Background: The ESMO Designated Centres (ESMO-DCs) of Integrated Oncology and Palliative Care (PC) Incentive Programme has grown steadily. We aimed to characterise the level of PC clinical services, education and research at ESMO-DCs.
Introduction
Palliative care is an inter-professional speciality aimed at providing effective symptom management, facilitating the communication and decision making needs throughout the disease trajectory for patients with advanced cancer and their families helping them to prepare for the end-of-life. Multiple studies have demonstrated benefits with timely integration of palliative care with routine oncologic care, such as improvements in physical and psychosocial symptoms, quality of life, satisfaction, costs of care and even survival [1] [2] [3] [4] [5] . With this growing body of evidence, there has been an increasing support for integration of palliative care and oncology from multiple professional organisations [6] [7] [8] .
Recognising the important role of palliative care in oncology, the European Society for Medical Oncology (ESMO) has developed multiple programmes to promote its integration, including the establishment of the ESMO Palliative Care Working Group in 1999 (renamed the ESMO Designated Centres Working Group in 2016) and funding the ESMO Palliative Care Fellowships. Since 2003, it has awarded the 'ESMO Designated Centres of Integrated Oncology and Palliative Care (ESMODCs)' status to self-nominating cancer centres that have undergone a rigorous anonymous review process by members of the ESMO Designated Centres Working Group to ensure they fulfil the 13 criteria related to advanced programme development consistent with established international standards [7] . Several characteristics of the ESMO-DC programme deserve emphasis:
1. Creating Incentives: The Designated Centre initiative aims to improve the relative advantage of adopting high quality palliative care by giving it status. In doing so, ESMO is trying to influence the culture of oncology to emphasise the commonality of purpose and goals between good cancer care and good palliative and supportive care, and that they are an irreducible unity. 2. Education with structure: Through the Designated Centre Programme, ESMO has tried to reduce perceived complexity of developing integrated palliative care services by providing concrete guidelines and achievable targets, and through the identification of hospitals and services that can serve as models and mentors for the development of new programmes. 3. Importance irrespective of scope: The recognition awarded is not dependant in the size of the institute or the number of patients treated. Both large cancer centres and relatively small oncology departments can be accredited as long as they clearly demonstrate that oncology and palliative care are well integrated as evidenced by meeting accreditation criteria. 4 . Quality of Integration does not have implications for other aspects of care: Accreditation as a Designated Centre does not involve or imply any statement about the quality of oncologic anti-tumour care. Standards of anti-tumour care are not evaluated in this process and accreditation does not imply that the centre offers the best of cancer care. It implies only that oncologic and palliative care are well integrated and that this itself is worthy of special recognition since is such an important aspect of cancer care delivery.
ESMO-DCs are considered as centres that deliver highly integrated care through different care models [9] . However, there is limited information in the public domain regarding the scope of specialist palliative care services offered at these accredited centres and the extent of palliative care delivery by their oncologists [10] . A detail characterisation of this information would help to set a benchmark for service development and to identify areas for further refinement of the ESMO-DC accreditation process. In 2009, we published a report on the 48 designated centres accredited in the first 5 years of the Designated Centre Programme [7] . Having now achieved a 'critical mass' of 200 accredited centres in 42 countries as of 2016, the ESMO Designated Centres Working Group undertook a survey to characterise the level of PC clinical services, education and research at ESMO-DCs. We also examined the level of palliative care provided by oncologists.
Methods

Eligibility criteria
This survey was sent to all 184 ESMO-DCs that were active at the time of study. The ESMO Designated Centre Working Group leadership received approval from ESMO to conduct this survey.
Survey development
We generated the survey questions after a comprehensive literature review [11] , including results from an international consensus on criteria for integration of oncology and palliative care [12] , and discussions among four panellists of the ESMO Designated Centres Working Group. The survey questions were developed based on the Donabedian tripartite division of structure, processes, and outcomes to evaluate the clinical, education and research aspects of specialist palliative care in cancer centres [13] , and also included questions related to palliative care interventions delivered by oncologists [10] . This survey was subsequently reviewed for face validity and readability. The final version consisted of 78 questions under four domains (supplementary Appendix S1, available at Annals of Oncology online). 
Survey process
The online survey was conducted between 22 March 2016 and 21 July 2016. We sent an invitation via e-mail to the palliative care programme leader or main contact for each ESMO-DC to participate in this voluntary survey. This e-mail contained a link to the survey in a secured website (Qualtrics, Provo, UT). To maximise the response rate, we sent a reminder e-mail weekly for the first 4 weeks after the initial contact, and provided as follow-up on an as needed basis. No financial incentives were provided.
Statistical considerations
Our primary outcome was the proportion of centres with the four different branches of palliative care (i.e. inpatient consultation teams, outpatient clinics, palliative care units and communitybased palliative care). This primary outcome was chosen because it provides an indication of the availability and integration of palliative care. With an anticipated response rate of 80%, we were able to estimate the proportion of centres that offer each branch of palliative care services with a margin of error of 63.6%.
We used standard descriptive statistics including means, standard deviations, ranges, proportions and frequencies, interquartile ranges to summarise the data.
Results
Centre characteristics
About 152/184 (83%) ESMO-DCs responded. As shown in Table 1 , a majority of respondents were from Europe (n ¼ 115, 76%) and approximately half (n ¼ 74, 49%) were cancer centres. The median number of inpatient beds was 555 (interquartile range 272-976). Among the respondents, 81 (53%) were palliative care department leaders, 60 (39%) were oncology department leaders, 10 (7%) were hospital executives and 30 (20%) had other roles.
Palliative care clinical programmes
A majority of programmes had been established for >10 years (Tables 2). A vast majority of programmes reported having inpatient consultation teams (n ¼ 136, 90%; 95% confidence interval [CI] 85%, 95%) and outpatient clinics (n ¼ 135, 89%; 95% CI 84%, 94%). About 107 (71%, 95% CI 64%, 78%) had palliative care beds/units and 75 (50%, 95% CI 42%, 58%) offered community-based palliative care. A high proportion of patients with advanced cancer were referred to these programmes (median 70%). The timing from palliative care referral to death was 21 days (14-45 days) for inpatients and 90 days (40-150 days) for outpatients. The most common programme names were 'Supportive and Palliative Care' (n ¼ 79, 52%) and 'Palliative Care' (n ¼ 65, 43%).
The ESMO-DCs provided a wide range of palliative care services with strong emphasis on symptom assessment and management, assistance in decision making, psychosocialspiritual care, family and care giver support and end of life planning (Table 3) . Oncologists in the ESMO-DCs provided primary level palliative care in the outpatient oncology setting. A majority of ESMO-DCs reported that the oncologists provide routine symptom screening and discuss goals of cancer treatments. However, the oncologists were less likely to have documented prognostic understanding, advanced care planning and end-oflife discussions which were issues commonly addressed by the palliative care services (Table 3) .
Staffing levels varied significantly (Table 4) ; however, the palliative care services at the ESMO-DCs had a strong multidisciplinary representation with robust staffing levels of palliative care physicians, nurses, social workers, chaplaincy and other paramedical professions. About 99 (65%) had physicians who were double-boarded in medical oncology and palliative medicine. A majority of the programme leaders received training in palliative medicine (n ¼ 102, 67%) and medical oncology (n ¼ 94, 62%). About 41 (27%) respondents reported that there was no board certification for palliative care specialisation in their countries. Education is a major element of the services provided by ESMODCs (Table 5) . A majority of centres provided combined educational activities for the oncology and palliative care staff (n ¼ 109, 73%) and continuing education for oncologists (n ¼ 109, 73%).
Half of the centres (n ¼ 78 52%) offered didactic palliative care curriculum for oncology fellows and more than one-third of programmes (n ¼ 59, 39%) had a palliative care fellowship training programme (Table 4 ). Other educational programmes included mandatory palliative care rotation for medical/haematology oncology fellows (n ¼ 47, 32%, median 8 weeks), radiation oncology fellows (n ¼ 26, 18%, median 4 weeks), paediatric oncology fellows (n ¼ 10, 7%, median 4 weeks), other residents/fellows (n ¼ 29, 21%, median 4 weeks) and medical students (n ¼ 36, 30%).
Research
Participation in research related to the palliative care of cancer patients is one of the accreditation criteria for the ESMO-DCs and all centres participated in research ( Table 5 ). The research teams were typically multidisciplinary. Approximately half of ESMO-DCs reported receiving research funding (n ¼ 76, 51%) in the last 3 years. Funding sources include local institution (n ¼ 46, 61%), private foundations (n ¼ 40, 53%), industry (n ¼ 38, 50%) and peer review grants (n ¼ 27, 36%). The scope and nature of the palliative care research endeavours varied widely; 53 (35%) centres conducted randomised controlled therapeutic trials and 38 (25%) conducted randomised non-therapeutic trials. The most commonly studied research topics were pain (n ¼ 104, 69%), psychosocial distress (n ¼ 67, 45%), and decision making (n ¼ 46, 31%).
Attitudes and beliefs towards ESMO designation
The ESMO designation was perceived to have a positive impact on multiple aspects of integrated oncology-palliative care programme development both before and after achieving the recognition status (Table 6 ). In particular, it helped to increase the status of the department (n ¼ 129, 86%) and institution (n ¼ 127, 85%), and was used for advertisement purpose (n ¼ 69, 46%).
Discussion
The ESMO-DCs incentive programme for the development of integrated oncology and palliative care services has grown in size over the past 13 years to include 200 centres at the time of writing. This survey has a high response rate and confirms that ESMO-DCs have a high level of palliative care integration and infrastructure, that they deliver palliative care to a large proportion of patients with advanced cancer with a wide variety of services, and that they are making important contributions in education and research. The high level of availability of the four branches of specialist palliative care among ESMO-DCs supports the robustness of this programme in context to other programme surveys. Among the ESMO-DCs, we found that inpatient consultation, outpatient clinics, palliative care units and community-based palliative care were present at 90%, 89%, 71% and 50% of services. These figures are in contrast to 89%, 66%, 31% and 26% among 71 National Cancer Institute designated cancer centres in a 2010 United States survey [14] , 72%, 64%, 39% and 21% among a sample of 183 ESMO/EAPC/MASCC centres in 2015 [15] , and 100%, 91%, 32% and 23% among 22 centres of the National Comprehensive Cancer Center Network in 2016 [16] .
ESMO-DCs were generally well staffed with an interdisciplinary team consisting of physicians, nurses and other professions. Taken together, we conclude that ESMO-DCs have a very high level of palliative care infrastructure. Less than 80% of services reported having dieticians [17] , chaplains, psychiatrists, psychologists or clinical pharmacists. Physicians who are double boarded in palliative medicine and oncology appear to be disproportionally represented and are present in two-thirds of ESMO-DCs; these dually trained individuals are well positioned to help catalyse the integration process through patient care, education and research [18] .
The presence of well integrated oncology and palliative care programmes facilitates an very high penetration of specialist palliative care access for patients with advanced cancer (70%), addressing all aspects of palliative care from symptom management, psychological support, communication, decision making, family support, palliative support network, end-of-life care, spiritual support and bereavement care.
We note that the median timing of consultation (3 months before death for outpatients) is shorter than the recommendation by a group of international experts on palliative care and oncology who suggested that the ideal time frame for outpatient referral to be between 6 and 24 months of life expectancy [19] . There are several potential reasons. First, it is often difficult to formulate a prognosis accurately, thus prognosis-based criteria may be more difficult to apply than need-based criteria [20, 21] . Second, among cancer patients with metastatic disease, performance status is often relatively well maintained until the last months of life when it sharply declines as symptom burden and distress tends to increases as the patient approaches end of life [22, 23] and higher care needs during this period may be more likely to trigger a palliative care referral. Third, some oncologists may choose to deliver palliative care interventions themselves instead of referring patients to specialist palliative care, despite the randomised evidence suggesting that involvement of specialist palliative care in addition to oncologic care can improve outcomes [1] [2] [3] [4] [5] . Finally, a small proportion of oncologists may still hesitate to refer patients to palliative care as long as they are on cancer treatments [24, 25] .
Many of the strategies to facilitate timely referral of patients with advanced cancer for palliative care identified in a recent review have been adopted by ESMO-DCs [11] . In some centres in North America, for instance, the use of the name 'Supportive Care' has been found to overcome the still present, but decreasing, stigma associated with 'palliative care' and reduce resistance to early referral [26] [27] [28] [29] [30] . Indeed, more than half of ESMO-DCs use the name 'supportive and palliative care'. Other strategies observed included participation of palliative care specialists in multidisciplinary tumour broads to improve communication and recognition of patients appropriate for a referral [18] , routine symptom screening in the oncology clinic coupled with automatic referrals based on standardised criteria [31] [32] [33] [34] [35] and increasing oncologists' understanding of palliative care through education and the importance of timely, rather than late, referral [25, 36] .
The survey also highlighted issues for development in many centres particularly with regards to the palliative care educational (24) 39 (26) 32 (21) 35 (23) 9 (6) 0 (0) Inpatient consultation team 24 (16) 112 (74) 8 (5) 7 (5) 1 (1) 0 (0) Outpatient clinic 41 (27) 93 (61) 10 (7) 6 (4) 2 (1) 0 (0) Home care
75 (49) 45 (30) 22 (14) 6 (4) 3 (2) 1 (1) a About 99 (65%) of ESMO-DCs reported that they had physicians who were double-boarded in medical oncology and palliative medicine. 21 (14) opportunities for oncologists and oncology education for palliative care clinicians. Didactic lectures, workshops and clinical rotations are particularly useful for trainees, while continuing medical education and conferences are appropriate for practicing clinicians [12] . Our survey highlighted that these educational opportunities were available in only half the ESMO-DCs. This may also explain the some of the variation in how oncologists delivered and documented palliative care interventions in their clinics; it was reported that only a minority of oncologists documented advance care planning and end-of-life discussions both of which are explicitly required in the global curriculum for medical oncologists [37] . Further work is needed to identify best strategies to empower delivery of primary palliative care by oncologists. The 'critical mass' survey of the ESMO-DCs illustrates how a professional society of oncologists can stimulate the development of palliative care through an incentivised recognition programme. The survey confirms that the 13 criteria required for ESMO designation set a robust framework for integration [7] , stimulated investment of resources into some palliative care programmes prior to accreditation, and raised the interest about palliative care among clinicians, trainees and patients. These criteria are under constant review for characteristics of inclusiveness (relevance to centres of all sizes) and discrimination (the ability to distinguished well developed integration from low level of integration) and additional criteria are under consideration. Overall, participating centres perceived that the ESMO designation enhanced the status of their institution, which was used for marketing purposes by many. Traditionally, cancer centres promoted their cancer treatments instead of supportive care services in advertisements [38] ; the ESMO designation is changing this with enhanced emphasis on integrated Palliative Care at their institutions. These observations support the effectiveness of this important programme as having created an incentive to programme development and in meeting its goal of providing 'education with structure' to facilitate and encourage the development of integrated oncology-palliative care services. 
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Research is another important aspect of integration because it (i) informs an evidence-based practice of palliative care, (ii) identifies novel interventions to improve patient care and optimal models to enhance healthcare delivery, (iii) creates opportunities for oncologists and palliative care teams to collaborate at an academic level, and (iv) consolidates the knowledge base and status of palliative care as a professional specialty. We found that only half of ESMO-DCs reported any research funding, which is essential to support research personnel. This, coupled with the observation that these centres only had a median of 1 (IQR 0-3) physician with at least 20% academic protected time, suggested that further research resources are needed. At the same time, it is encouraging to see that despite the limited resources, approximately half (46%) of the ESMO-DCs reported that they conducted randomised controlled trials, when only 6% of palliative oncology literature consisted of randomised controlled trials [39] . The topics of research varied widely reflecting the diversity of the palliative care spectrum; a majority of ESMO-DCs were engaged in studies on physical symptoms such as pain, anorexiacachexia and fatigue. Studies related to integration on oncology and palliative care, such as decision making surrounding palliative cancer treatments, health outcomes research and care pathways, were conducted in 10-30% of centres. As centres of excellence with established clinical infrastructure and large patient volumes, ESMO-DCs are well positioned to conduct ground breaking studies to guide patient care and policy development, provided that adequate resources and academic leadership are available.
With 200 centres in 42 countries, the ESMO experience is unmatched in its penetration and in the scope of palliative care services offered. An overwhelming majority of ESMO-DCs undergo the reaccreditation process every 3 years. The high response rate and the large cohort of centres represent strengths of this study. Acknowledged limitations of this survey include its reliance on the institutional and programme leaders to provide the data (or approximate data in some instances) without independent verification.
In summary, this survey highlights the success of the ESMODCs programme and the very high level of integrated oncology and palliative care infrastructure in the ESMO-DCs. ESMO is committed to the development of cancer services across Europe and the rest of the world to meet the highest standards of cancer care; the provision of integrated oncology and palliative care is an integral part of that vision. ESMO aims to make this standard of integration the norm of care rather than the exception, and this large dataset provides support to the use of the 13 criteria as a structured, pragmatic model for programme development. The critical mass survey indicates that substantial progress has been made and identifies further opportunities for advancement.
